<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>39(12)</volume><submitter>Khanna J</submitter><funding>Allergan plc</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Reoperation after primary breast augmentation remains an important clinical issue.&lt;h4>Objective&lt;/h4>The authors sought to evaluate incidence and causes of reoperation in patients who underwent primary augmentation.&lt;h4>Methods&lt;/h4>This retrospective, noninterventional study conducted at 16 Canadian sites reviewed medical records and patient-completed questionnaires of women who underwent primary breast augmentation with smooth or textured Natrelle Inspira implants containing TruForm 1 or TruForm 2 gel. Patients were aged ≥22 years, received implants via inframammary fold incision, and returned for follow-up at 2 to 4 years.&lt;h4>Results&lt;/h4>A total of 319 women received Inspira implants (smooth TruForm 2, n = 205; textured TruForm 2, n = 99; smooth or textured TruForm 1, n = 15). At follow-up, 30 women (9.4%) had undergone reoperation, including 19 (9.3%) in the smooth TruForm 2 subgroup and 9 (9.1%) in the textured TruForm 2 subgroup. The mean time to reoperation was 1.2 years; the risk rate for reoperation was 9.9% at 3 years. The most common reasons for reoperation were implant malposition (36.7%), capsular contracture (33.3%), and the patient's request for a change in implant size or style (20.0%). Most women were very or somewhat satisfied with the initial surgery (89.3% overall; 90.7% smooth TruForm 2; 86.9% textured TruForm 2). Thirty-four women (10.7%) reported adverse events, including 20 (9.8%) in the smooth TruForm 2 subgroup and 14 (14.1%) in the textured TruForm 2 subgroup.&lt;h4>Conclusions&lt;/h4>This analysis suggests that Natrelle Inspira TruForm 2 implants are safe when used in primary breast augmentation, resulting in low reoperation rates that are consistent with those for other breast implants.&lt;h4>Level of evidence: 4&lt;/h4></pubmed_abstract><journal>Aesthetic surgery journal</journal><pagination>1342-1349</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6853655</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Reoperation Rate After Primary Augmentation With Smooth, Textured, High Fill, Cohesive, Round Breast Implants (RANBI-I Study).</pubmed_title><pmcid>PMC6853655</pmcid><pubmed_authors>Khanna J</pubmed_authors><pubmed_authors>Nguyen S</pubmed_authors><pubmed_authors>Mosher M</pubmed_authors><pubmed_authors>Garzon D</pubmed_authors><pubmed_authors>Whidden P</pubmed_authors><pubmed_authors>Bhogal M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reoperation Rate After Primary Augmentation With Smooth, Textured, High Fill, Cohesive, Round Breast Implants (RANBI-I Study).</name><description>&lt;h4>Background&lt;/h4>Reoperation after primary breast augmentation remains an important clinical issue.&lt;h4>Objective&lt;/h4>The authors sought to evaluate incidence and causes of reoperation in patients who underwent primary augmentation.&lt;h4>Methods&lt;/h4>This retrospective, noninterventional study conducted at 16 Canadian sites reviewed medical records and patient-completed questionnaires of women who underwent primary breast augmentation with smooth or textured Natrelle Inspira implants containing TruForm 1 or TruForm 2 gel. Patients were aged ≥22 years, received implants via inframammary fold incision, and returned for follow-up at 2 to 4 years.&lt;h4>Results&lt;/h4>A total of 319 women received Inspira implants (smooth TruForm 2, n = 205; textured TruForm 2, n = 99; smooth or textured TruForm 1, n = 15). At follow-up, 30 women (9.4%) had undergone reoperation, including 19 (9.3%) in the smooth TruForm 2 subgroup and 9 (9.1%) in the textured TruForm 2 subgroup. The mean time to reoperation was 1.2 years; the risk rate for reoperation was 9.9% at 3 years. The most common reasons for reoperation were implant malposition (36.7%), capsular contracture (33.3%), and the patient's request for a change in implant size or style (20.0%). Most women were very or somewhat satisfied with the initial surgery (89.3% overall; 90.7% smooth TruForm 2; 86.9% textured TruForm 2). Thirty-four women (10.7%) reported adverse events, including 20 (9.8%) in the smooth TruForm 2 subgroup and 14 (14.1%) in the textured TruForm 2 subgroup.&lt;h4>Conclusions&lt;/h4>This analysis suggests that Natrelle Inspira TruForm 2 implants are safe when used in primary breast augmentation, resulting in low reoperation rates that are consistent with those for other breast implants.&lt;h4>Level of evidence: 4&lt;/h4></description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Nov</publication><modification>2024-11-13T00:30:22.781Z</modification><creation>2020-05-21T20:10:14Z</creation></dates><accession>S-EPMC6853655</accession><cross_references><pubmed>30383228</pubmed><doi>10.1093/asj/sjy289</doi></cross_references></HashMap>